Here are the 424B prospectus supplements from Viridian Therapeutics, Inc. (VRDN) in our archive over the last 12 months, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 424B covers the supplement that carries the terms of a priced offering, so if you follow VRDN and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full VRDN filings page.
Viridian Therapeutics is offering $225.0 million aggregate principal amount of 1.75% convertible senior notes due May 15, 2032, with an underwriter option for an additional $25.0 million. The notes carry an initial conversion rate of 40.5680 shares per $1,000 (initial conversion price ~$24.65 per share), pay interest semi-annually at 1.75%, and may be settled in cash, shares or a combination at the company’s election. The offering is concurrent with a separate public equity offering (aggregate of $125.0 million, or up to $143.75 million if the option is exercised) and Viridian expects to use proceeds, together with the concurrent equity proceeds, to repay the Hercules Loan and fund R&D, market expansion studies and general corporate purposes. The supplement also discloses positive topline REVEAL-2 phase 3 results for elegrobart and an anticipated BLA submission in Q1 2027.
Viridian Therapeutics is offering 7,352,942 shares of common stock at a public offering price of $17.00 per share, expected to raise approximately $117.0 million in net proceeds before expenses (assuming no exercise of the underwriters' option).
Concurrently, Viridian is conducting a separate Concurrent Convertible Notes Offering of 1.75% convertible senior notes due 2032 with an aggregate principal amount of $225.0 million (or $250.0 million if the underwriters’ option is exercised). The company intends to use proceeds to repay the Hercules loan, fund market expansion studies for its TED franchise and advance R&D, and for working capital and general corporate purposes.
Viridian Therapeutics is offering $150.0 million aggregate principal amount of % convertible senior notes due 2032. The notes pay semi‑annual interest, mature on May 15, 2032, and include an underwriter option to purchase up to an additional $22.5 million. Conversions may be settled in cash, shares or a combination and are permitted only upon specified triggers until February 15, 2032, after which conversions are permitted at holder election. The offering is concurrent with a planned $100.0 million equity offering and the company expects to use proceeds to repay its Hercules secured loan, fund market expansion studies for its TED franchise, advance earlier‑stage R&D, and for working capital. Separately, Viridian announced positive topline REVEAL‑2 Phase 3 results for elegrobart (N=204), meeting primary and key secondary endpoints, and plans a BLA submission in Q1 2027.
Viridian Therapeutics is offering an aggregate of $100,000,000 of common stock and Series B non‑voting convertible preferred stock. Each Series B share converts into 66.67 shares of common stock, subject to a Series B Beneficial Ownership Limitation. The company is conducting a concurrent offering of convertible senior notes in an aggregate principal amount of $150,000,000 (with an over-allotment option) that is not contingent on this equity offering. Recent clinical news: topline REVEAL-2 phase 3 results for elegrobart met primary and key secondary endpoints with strong statistical significance (p<0.0001) and the company plans to submit a BLA in Q1 2027. The company’s common stock trades on Nasdaq at $14.06 per share (last reported on May 4, 2026).